Company intelligence / Profile preview
Eradivir
West Lafayette, Indiana, United Stateseradivir.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Eradivir's lead drug EV25 for influenza has completed Phase 1 trials where it was found to be well-tolerated in humans. The company has begun a Phase 2 challenge study as of March 2025, with preliminary data expected to be available in September 2025. In preclinical studies, EV25 demonstrated ability to quickly eliminate influenza virus in the lungs even when taken 96 hours post-infection and showed effectiveness against several flu strains, including pandemic strains and those resistant to current flu drugs.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Eradivir.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eradivir.